Refining the approach to vaccines against influenza A viruses with pandemic potential

Future Virology

Volumn 10, Issue 9, 2015, Pages 1033-1047

  Czako, Rita ^a   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

antigenic mismatch; avian influenza; pandemic influenza; prepandemic vaccine; prime boost

Indexed keywords

AVIAN INFLUENZA VACCINE; EPITOPE; INFLUENZA VACCINE;

ANTIBODY RESPONSE; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; CROSS PROTECTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A VIRUS; INFLUENZA VACCINATION; META ANALYSIS (TOPIC); NARCOLEPSY; NONHUMAN; PANDEMIC INFLUENZA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRUS IDENTIFICATION;

EID: 84942614642     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.15.69     Document Type: Review

References (176)

1. Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Fields Virology. David M, Knipe PMH (Eds). Lippincott Williams & Wilkins PA, USA, 1186-1243 (2013
2. Yoon S-W, Webby RJ, Webster RG. Evolution and ecology of influenza a viruses. Curr. Top. Microbiol. Immunol. 385, 359-375 (2014
3. Tong S, Li Y, Rivailler P et al. A distinct lineage of influenza A virus from bats. Proc. Natl Acad. Sci. USA. 109(11), 4269-4274 (2012
4. Tong S, Zhu X, Li Y et al. New world bats harbor diverse influenza a viruses. PLoS Pathog. 9(10), e1003657 (2013
5. Grohskopf LA, Olsen SJ, Sokolow LZ et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP) - United States, 2014-15 influenza season. MMWR. Morb. Mortal. Wkly Rep. 63(32), 691-697 (2014
6. Ampofo WK, Baylor N, Cobey S et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir. Viruses 6(2), e141-145 (2012
7. Jackson LA. Using surveillance to evaluate influenza vaccine effectiveness. J. Infect. Dis. 199(2), 155-158 (2009
8. Richard SA, Viboud C, Miller MA. Evaluation of southern hemisphere influenza vaccine recommendations. Vaccine 28(15), 2693-2699 (2010
9. Kilbourne ED. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 12(1), 9-14 (2006
10. World Health Organization.Cumulative number of confirmed human cases for avian influenza A (H5N1) reported to WHO, 2003-2015.www.who.int/influenza/human-Animal-interface/H5N1-cumulative-table-Archives/en
11. Broadbent AJ, Subbarao K. Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr. Opin. Virol. 1(4), 254-262 (2011
12. Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360(25), 2605-2615 (2009
13. Kawaoka Y, Krauss S, Webster RG. Avian-tohuman transmission of the PB1 gene of influenza a viruses in the 1957 and 1968 pandemics. J. Virol. 63(11), 4603-4608 (1989
14. Swayne DE. Impact of vaccines and vaccination on global control of avian influenza. Avian Dis. 56(4 Suppl), 818-828 (2012
15. Laver WG, Webster RG. Studies on the origin of pandemic influenza. 3. Evidence implicating duck and equine influenza viruses as possible progenitors of the Hong Kong strain of human influenza. Virology 51(2), 383-391 (1973
16. Scholtissek C, Rohde W, Von Hoyningen V, Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology 87(1), 13-20 (1978
17. Wendel I, Rubbenstroth D, Doedt J et al. The avian-origin PB1 gene segment facilitated replication and transmissibility of the H3N2/1968 pandemic influenza virus. J. Virol. 89(8), 4170-4179 (2015
18. Cox NJ, Trock SC, Burke SA. Pandemic preparedness and the Influenza Risk Assessment Tool (IRAT). Curr. Top. Microbiol. Immunol. 385 119-136 (2014
19. Trock SC, Burke SA, Cox NJ. Development of an influenza virologic risk assessment tool. Avian Dis. 56(4 Suppl), 1058-1061 (2012
20. Schrauwen EJA, Herfst S, Leijten LM et al. The multibasic cleavage site in H5N1 virus is critical for systemic spread along the olfactory and hematogenous routes in ferrets. J. Virol. 86(7), 3975-3984 (2012
21. Suguitan AL, Matsuoka Y, Lau Y-F et al. The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/ 2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals. J. Virol. 86(5), 2706-2714 (2012
22. Yoon S-W, Kayali G, Ali MA, Webster RG, Webby RJ, Ducatez MF. A single amino acid at the hemagglutinin cleavage site contributes to the pathogenicity but not the transmission of Egyptian highly pathogenic H5N1 influenza virus in chickens. J. Virol. 87(8), 4786-4788 (2013
23. Herfst S, Schrauwen EJA, Linster M et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336(6088), 1534-1541 (2012
24. Imai M, Watanabe T, Hatta M et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486(7403), 420-428 (2012
25. Guan Y, Shortridge KF, Krauss S, Webster RG. Molecular characterization of H9N2 influenza viruses: were they the donors of the internal genes of H5N1 viruses in Hong Kong?. Proc. Natl Acad. Sci. USA 96(16), 9363-9367 (1999
26. Li X, Shi J, Guo J et al. Genetics, receptor binding property, and transmissibility in mammals of naturally isolated H9N2 avian influenza viruses. PLoS Pathog. 10(11), e1004508 (2014
27. Pu J, Wang S, Yin Y et al. Evolution of the H9N2 influenza genotype that facilitated the genesis of the novel H7N9 virus. Proc. Natl Acad. Sci. USA 112(2), 548-553 (2015
28. Hoffmann E, Stech J, Leneva I et al. Characterization of the influenza a virus gene pool in avian species in southern China: was H6N1 a derivative or a precursor of H5N1?. J. Virol. 74(14), 6309-6315 (2000
29. Liu M, Li X, Yuan H et al. Genetic diversity of avian influenza A (H10N8) virus in live poultry markets and its association with human infections in China. Sci. Rep. 5 7632-7632 (2015
30. Centers for Disease Control and Prevention (CDC). Update: influenza A (H3N2)v transmission and guidelines - five states, 2011. MMWR. Morb. Mortal. Wkly Rep. 60(51-52), 1741-1744 (2012
31. Li Q, Zhou L, Zhou M et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N. Engl. J. Med. 370(6), 520-532 (2014
32. Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368(20), 1888-1897 (2013
33. Zhang Q, Shi J, Deng G et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 341(6144), 410-414 (2013
34. Smith GJD, Vijaykrishna D, Bahl J et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza a epidemic. Nature 459(7250), 1122-1125 (2009
35. Capua I, Terregino C, Cattoli G, Mutinelli F, Rodriguez JF. Development of a DIVA (Differentiating Infected from Vaccinated Animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza. Avian Pathol. 32(1), 47-55 (2003
36. Cattoli G, Fusaro A, Monne I et al. Evidence for differing evolutionary dynamics of A/H5N1 viruses among countries applying or not applying avian influenza vaccination in poultry. Vaccine 29(50), 9368-9375 (2011
37. Bertran K, Moresco K, Swayne DE. Impact of vaccination on infection with Vietnam H5N1 high pathogenicity avian influenza virus in hens and the eggs they lay. Vaccine 33(11), 1324-1330 (2015
38. Lee C-W, Senne DA, Suarez DL. Effect of vaccine use in the evolution of Mexican lineage H5N2 avian influenza virus. J. Virol. 78(15), 8372-8381 (2004
39. Ferguson NM, Cummings DaT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 442(7101), 448-452 (2006
40. World Health Organization. World Health Organization. Pandemic influenza vaccine manufacturing process and timeline. Pandemic (H1N1) 2009 briefing note 7 (2009). www.who.int/csr/disease/swineflu/notes/h1n1-vaccine-20090806/en
41. Jennings LC, Monto AS, Chan PKS, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect. Dis. 8(10), 650-658 (2008
42. Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg. Infect. Dis. 12(1), 66-72 (2006
43. Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR, Kanesa-Thasan N. A cell culture-derived MF59-Adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci. Transl. Med. 6(234), 234ra255 (2014
44. Stohr K. Vaccinate before the next pandemic?. Nature 465(7295), 161 (2010
45. World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits (2011). www.who.int/influenza/resources/pip-framework/en
46. Tricco AC, Chit A, Soobiah C et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-Analysis. BMC Med. 11 153-153 (2013
47. Hensley SE. Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. Curr. Opin. Virol. 8 85-89 (2014
48. Li Y, Myers JL, Bostick DL et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp. Med. 210(8), 1493-1500 (2013
49. Linderman SL, Chambers BS, Zost SJ et al. Potential antigenic explanation for atypical H1N1 infections among middle-Aged adults during the 2013-2014 influenza season. Proc. Natl Acad. Sci. USA 111(44), 15798-15803 (2014
50. Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-Adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136(2), 168-175 (2000
51. Halloran ME, Piedra PA, Longini IM Jr et al. Efficacy of trivalent, cold-Adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine 25(20), 4038-4045 (2007
52. Mendelman PM, Rappaport R, Cho I et al. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/ 2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J. 23(11), 1053-1055 (2004
53. Monto AS, Ohmit SE, Petrie JG et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N. Engl. J. Med. 361(13), 1260-1267 (2009
54. Ohmit SE, Victor JC, Rotthoff JR et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 355(24), 2513-2522 (2006
55. Flannery B, Clippard J, Zimmerman RK et al. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb. Mortal. Wkly Rep. 64(1), 10-15 (2015
56. Abdel-Ghafar A-N, Chotpitayasunondh T, Gao Z et al. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358(3), 261-273 (2008
57. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Wkly Epidemiol. Rec. 89(42), 457-464 (2014
58. Halder N, Kelso JK, Milne GJ. A modelbased economic analysis of pre-pandemic influenza vaccination cost-effectiveness. BMC Infect. Dis. 14 266-266 (2014
59. Ekiert DC, Bhabha G, Elsliger M-A et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924), 246-251 (2009
60. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328(5976), 357-360 (2010
61. Sangster MY, Baer J, Santiago FW et al. B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin. Vaccine Immunol. 20(6), 867-876 (2013
62. Wrammert J, Koutsonanos D, Li GM et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208(1), 181-193 (2011
63. Corti D, Voss J, Gamblin SJ et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333(6044), 850-856 (2011
64. Nachbagauer R, Wohlbold TJ, Hirsh A et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 88(22), 13260-13268 (2014
65. Cobbin JC, Zeng W, Jackson DC, Brown LE. Different arms of the adaptive immune system induced by a combination vaccine work in concert to provide enhanced clearance of influenza. PLoS ONE 9(12), e115356 (2014
66. Taylor PM, Askonas BA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 58(3), 417-420 (1986
67. Li J, Arevalo MT, Chen Y, Chen S, Zeng M. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine. Int. J. Infect. Dis. 27 37-43 (2014
68. Guo H, Santiago F, Lambert K, Takimoto T, Topham DJ. T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J. Virol. 85(1), 448-455 (2010
69. Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J. Immunol. 160(1), 322-327 (1998
70. Wilkinson TM, Li CKF, Chui CSC et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18(2), 274-280 (2012
71. Sridhar S, Begom S, Bermingham A et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19(10), 1305-1312 (2013
72. Crowe BA, Brühl P, Gerencer M et al. Evaluation of the cellular immune responses induced by a non-Adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 29(2), 166-173 (2010
73. Kreijtz JH, De Mutsert G, Van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J. Virol. 82(11), 5161-5166 (2008
74. Hayward AC, Wang L, Goonetilleke N et al. Natural T cell mediated protection against seasonal and pandemic influenza: results of the flu watch cohort study. Am. J. Respir. Crit. Care Med. 191( 12), 1422-1431 (2015
75. Baras B, Stittelaar KJ, Simon JH et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3(1), e1401 (2008
76. Suguitan AL, Mcauliffe J, Mills KL et al. Live, attenuated influenza a H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3(9), e360-e360 (2006
77. Chen Z, Baz M, Lu J et al. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J. Virol. 88(12), 7016-7023 (2014
78. Baz M, Paskel M, Matsuoka Y et al. A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets. J. Virol. 89(3), 1652-1659 (2015
79. Chen H, Matsuoka Y, Swayne D et al. Generation and characterization of a cold-Adapted influenza a H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 21(27-30), 4430-4436 (2003
80. Carter DM, Bloom CE, Kirchenbaum GA et al. Cross-protection against H7N9 influenza strains using a live-Attenuated H7N3 virus vaccine. Vaccine 33(1), 108-116 (2015
81. Chen Z, Santos C, Aspelund A et al. Evaluation of live attenuated influenza A virus H6 vaccines in mice and ferrets. J. Virol. 83(1), 65-72 (2009
82. Min JY, Vogel L, Matsuoka Y et al. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J. Virol. 84(22), 11950-11960 (2010
83. Tang LH, Lim JH, Kuah LF, Lau YF. Complete protection against lethal challenge of novel H7N9 virus with heterologous inactivated H7 vaccine in mice. Vaccine 32(42), 5375-5378 (2014
84. Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-Adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191(8), 1210-1215 (2005
85. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370(9587), 580-589 (2007
86. Fazekas G, Martosne-Mendi R, Jankovics I, Szilvasy I, Vajo Z. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clin. Vaccine Immunol. 16(4), 437-443 (2009
87. Moris P, Van Der Most R, Leroux-Roels I et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J. Clin. Immunol. 31(3), 443-454 (2011
88. Nolan T, Richmond PC, Formica NT et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26(50), 6383-6391 (2008
89. Mahallawi WH, Kasbekar AV, Mccormick MS et al. Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-Associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses. J. Virol. 87(10), 5331-5339 (2013
90. Nicholson KG, Abrams KR, Batham S et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-Adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect. Dis. 11(2), 91-101 (2011
91. Nicholson KG, Thompson CI, Klap JM et al. Safety and immunogenicity of whole-virus, alum-Adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine 28(1), 171-178 (2009
92. Khurana S, Verma N, Yewdell JW et al. Mf59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3(85), 85ra48 (2011
93. Jegaskanda S, Reading PC, Kent SJ. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J. Immunol. 193(2), 469-475 (2014
94. Andrews SF, Kaur K, Pauli NT, Huang M, Huang Y, Wilson PC. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. J. Virol. 89(6), 3308-3317 (2015
95. Palese P, Wang TT. Why do influenza virus subtypes die out?. A hypothesis. MBio 2( 5 ), pii: e00150-11 (2011
96. Li G-M, Chiu C, Wrammert J et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl Acad. Sci. USA 109(23), 9047-9052 (2012
97. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus Res. 178(1), 78-98 (2013
98. Karron RA, Callahan K, Luke C et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J. Infect. Dis. 199(5), 711-716 (2009
99. Karron RA, Talaat K, Luke C et al. Evaluation of two live attenuated cold-Adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27(36), 4953-4960 (2009
100. Talaat KR, Karron RA, Callahan KA et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 27(28), 3744-3753 (2009
101. Coelingh KL, Luke CJ, Jin H, Talaat KR. Development of live attenuated influenza vaccines against pandemic influenza strains. Expert Rev. Vaccines 13(7), 855-871 (2014
102. Centers for Disease Control and Prevention (CDC). Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. MMWR Morb. Mortal. Wkly Rep. 58(48), 1351-1356 (2009
103. Rudenko L, Isakova-Sivak I. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus. Expert Rev. Vaccines 14(3), 395-412 (2015
104. Rudenko L, Kiseleva I, Naykhin AN et al. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind Phase I study of live attenuated H7N3 influenza vaccine. PLoS ONE 9(2), e87962 (2014
105. Ehrlich HJ, Muller M, Oh HM et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358(24), 2573-2584 (2008
106. Couch RB, Patel SM, Wade-Bowers CL, Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS ONE 7(12), e49704 (2012
107. Krammer F, Jul-Larsen A, Margine I et al. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin. Vaccine Immunol. 21(8), 1153-1163 (2014
108. Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA. A Phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine 28(17), 3025-3029 (2010
109. Stephenson I, Nicholson KG, Hoschler K et al. Antigenically distinct MF59-Adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med. 359(15), 1631-1633 (2008
110. Dauvilliers Y, Arnulf I, Lecendreux M et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in france. Brain 136(Pt 8), 2486-2496 (2013
111. Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7(3), e33536 (2012
112. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7(3), e33723 (2012
113. Heier MS, Gautvik KM, Wannag E et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med. 14(9), 867-871 (2013
114. Miller E, Andrews N, Stellitano L et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 346 f794 (2013
115. OFlanagan D, Barret AS, Foley M et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Euro Surveill. 19(17), 15-25 (2014
116. Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J. Intern. Med. 275(2), 172-190 (2014
117. Dauvilliers Y, Montplaisir J, Cochen V et al. Post-H1N1 narcolepsy-cataplexy. Sleep 33(11), 1428-1430 (2010
118. Harris T, Wong K, Stanford L, Fediurek J, Crowcroft N, Deeks S. Did narcolepsy occur following administration of AS03-Adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada?. A review of post-marketing safety surveillance data. Euro Surveill. 19(36), pii: 20900 (2014
119. Jacob L, Leib R, Ollila HM, Bonvalet M, Adams CM, Mignot E. Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-Adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav. Immun. 47, 44-57 (2014
120. Duffy J, Weintraub E, Vellozzi C, Destefano F. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States. Neurology 83(20), 1823-1830 (2014
121. Yih WK, Lee GM, Lieu TA et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) system, 2009-2010. Am. J. Epidemiol. 175(11), 1120-1128 (2012
122. Vaarala O, Vuorela A, Partinen M et al. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-Associated narcolepsy risk. PLoS ONE 9(12), e114361 (2014
123. Singh AK, Mahlios J, Mignot E. Genetic association, seasonal infections and autoimmune basis of narcolepsy. J. Autoimmun. 43 26-31 (2013
124. Sturkenboom MC. The narcolepsy-pandemic influenza story: can the truth ever be unraveled?. Vaccine 33(Suppl. 2), B6-B13 (2015
125. Committee for Proprietary MedicinalProducts. Note for guidance on harmonisation of requirements for influenza vaccines.CPMP/BWP/214/96 (1997). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003945.pdf
126. Bandell A, Woo J, Coelingh K. Protective efficacy of live-Attenuated influenza vaccine (multivalent, ann arbor strain): a literature review addressing interference. Expert Rev. Vaccines 10(8), 1131-1141 (2011
127. Edwards KM, Dupont WD, Westrich MK, Plummer WD, Palmer PS, Wright PF. A randomized controlled trial of cold-Adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169(1), 68-76 (1994
128. Coudeville L, Andre P, Bailleux F, Weber F, Plotkin S. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum. Vaccin. 6(10), 841-848 (2010
129. Khurana S, Suguitan AL, Rivera Y et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6(4), e1000049 (2009
130. Mallory RM, Malkin E, Ambrose CS et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE 5(10), e13755 (2010
131. Rudenko L, Van Den Bosch H, Kiseleva I et al. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to who for pandemic influenza preparedness in developing countries. Vaccine 29(Suppl. 1), A40-44 (2011
132. Rudenko L, Desheva J, Korovkin S et al. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (Phase I-II clinical trials). Influenza Other Respir. Viruses 2(6), 203-209 (2008
133. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006
134. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13-14), 1732-1737 (2001
135. Talaat KR, Luke CJ, Khurana S et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J. Infect. Dis. 209(12), 1860-1869 (2014
136. Goji NA, Nolan C, Hill H et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/ 2004 (H5N1) vaccine after priming with an antigenic variant. J. Infect. Dis 198(5), 635-641 (2008
137. Cate TR, Couch RB, Kasel JA, Six HR. Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence. J. Infect. Dis. 136 Suppl S450-455 (1977
138. Meiklejohn G, Eickhoff TC, Graves P. Antibody response of young adults to experimental influenza A/New Jersey/76 virus vaccines. J. Infect. Dis. 136 Suppl S456-S459 (1977
139. Wise TG, Dolin R, Mazur MH, Ennis FA. Serologic responses after two sequential doses of influenza A/New Jersey/76 virus vaccine in normal young adults. J. Infect. Dis. 136 Suppl S496-499 (1977
140. Edelman R, Scheidt KB. Sequential immunization of laboratory personnel with influenza A/New Jersey/76 split- and whole-virus vaccines. J. Infect. Dis. 136 Suppl S500-506 (1977
141. Pandemic working group of the Medical Research Council (UK) Committee on influenza and other respiratory virus vaccines.Antibody responses and reactogenicity of graded doses of inactivated influenza A/New Jersey/76 whole-virus vaccine in humans. J. Infect. Dis. 136 Suppl S475-483 (1977
142. Ledgerwood JE, Wei CJ, Hu Z et al. DNA priming and influenza vaccine immunogenicity: two Phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11(12), 916-924 (2011
143. Ledgerwood JE, Zephir K, Hu Z et al. Prime-boost interval matters: a randomized Phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J. Infect. Dis. 208(3), 418-422 (2013
144. Gurwith M, Lock M, Taylor EM et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, Phase 1 study. Lancet Infect. Dis. 13(3), 238-250 (2013
145. Ehrlich HJ, Muller M, Fritsch S et al. A cell culture (vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 200(7), 1113-1118 (2009
146. Lin JT, Li CG, Wang X et al. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J. Infect. Dis. 199(2), 184-187 (2009
147. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J. Infect. Dis. 197(4), 580-583 (2008
148. Belshe RB, Frey SE, Graham IL et al. Immunogenicity of avian influenza A/Anhui/01/2005 (H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. JAMA 312(14), 1420-1428 (2014
149. Winokur PL, Patel SM, Brady R et al. Safety and immunogenicity of a single low dose or high dose of clade 2 influenza A(H5N1) inactivated vaccine in adults previously primed with clade 1 influenza A(H5N1) vaccine. J. Infect. Dis. 212( 4), 525-530 (2015
150. Babu TM, Levine M, Fitzgerald T et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 32(50), 6798-6804 (2014
151. Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-Adjuvanted and MF59-Adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357(9272), 1937-1943 (2001
152. Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to influenza H5N1 with MF59-Adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21(15), 1687-1693 (2003
153. Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106(19), 7962-7967 (2009
154. Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3(5), 521-530 (2013
155. Halliley JL, Khurana S, Krammer F et al. High affinity H7 head and stalk domainspecific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine. J. Infect. Dis. doi: 10.1093/infdis/jiv210 (2015) (Epub ahead of print
156. Crank MC, Gordon IJ, Yamshchikov GV et al. Phase 1 study of pandemic H1 DNA vaccine in healthy adults. PLoS ONE 10(4), e0123969 (2015
157. Frey SE, Bernstein DI, Brady RC et al. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine 33(1), 163-173 (2015
158. Uno S, Kimachi K, Kei J et al. Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial. Microbiol. Immunol. 55(11), 783-789 (2011
159. Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. A heterologous MF59-Adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin. Vaccine Immunol. 17(11), 1817-1819 (2010
160. Wang W, Lu J, Cotter CR, Wen K, Jin H, Chen Z. Identification of critical residues in the hemagglutinin and neuraminidase of influenza virus H1N1pdm for vaccine virus replication in embryonated chicken eggs. J. Virol. 87(8), 4642-4649 (2013
161. Krenn BM, Egorov A, Romanovskaya-Romanko E et al. Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS ONE 6(4), e18577 (2011
162. Nakowitsch S, Wolschek M, Morokutti A et al. Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. Vaccine 29(19), 3517-3524 (2011
163. Van Der Velden MVW, Fritz R, Pöllabauer EM et al. Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. J. Infect. Dis. 209(1), 12-23 (2014
164. Aichinger G, Grohmann-Izay B, Van Der Velden MVW et al. Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults. Clin. Vaccine Immunol. 22(1), 46-55 (2015
165. Ehrlich HJ, Müller M, Kollaritsch H et al. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Vaccine 30(30), 4543-4551 (2012
166. Van Der Velden MVW, Geisberger A, Dvorak T et al. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients. Clin. Vaccine Immunol. 21(6), 867-876 (2014
167. Chia M-Y, Hu AY-C, Tseng Y-F et al. Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets. PLoS ONE 10(3), e0120793-e0120793 (2015
168. Kim JH, Jacob J. DNA vaccines against influenza viruses. Curr. Top. Microbiol. Immunol. 333 197-210 (2009
169. Kreijtz JH, Goeijenbier M, Moesker FM et al. Safety and immunogenicity of a modifiedvaccinia-virus-Ankara-based influenza a H5N1 vaccine: a randomised, double-blind Phase 1/2a clinical trial. Lancet Infect. Dis. 14(12), 1196-1207 (2014
170. Lin J, Calcedo R, Vandenberghe LH, Bell P, Somanathan S, Wilson JM. A new genetic vaccine platform based on an adenoassociated virus isolated from a rhesus macaque. J. Virol. 83(24), 12738-12750 (2009
171. Sheahan T, Whitmore A, Long K et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J. Virol. 85(1), 217-230 (2011
172. Dinapoli JM, Nayak B, Yang L et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 84(3), 1489-1503 (2010
173. Schwartz JA, Buonocore L, Suguitan A Jr et al. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J. Virol. 85(9), 4602-4605 (2011
174. Even-Or O, Samira S, Ellis R, Kedar E, Barenholz Y. Adjuvanted influenza vaccines. Expert Rev. Vaccines 12(9), 1095-1108 (2013
175. Holloway R, Rasmussen SA, Zaza S, Cox NJ, Jernigan DB. Updated preparedness and response framework for influenza pandemics. MMWR Recomm. Rep. 63(RR-06), 1-18 (2014
176. Lerner H, Berg C. The concept of health in one health and some practical implications for research and education: what is one health?. Infect. Ecol. Epidemiol. 5, 25300 (2015